BlueRock’s Cell+Gene platform harnesses the power of cells for new medicines across Neurology, Cardiology and Autoimmunity. BlueRock’s cell differentiation technology recapitulates the cell’s developmental biology to produce native cell therapies, which can be further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. The company was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant.
BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring regenerative medicines to all who would benefit. The company is expanding staff at all locations. Contact us to learn about rewarding career opportunities in New York, Cambridge, and Toronto.